OMER241115P5000
- 0.72
- 0.000.00%
Omeros Newsroom
Omeros Gets FDA Rare Pediatric Disease Designation for Renal Disorder Treatment
Express News | FDA Grants Rare Pediatric Disease Designation to Omeros’ Masp-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
Needham Sticks to Its Hold Rating for Omeros (OMER)
Omeros | 10-Q: Q2 2024 Earnings Report
Express News | Omeros Corporation Reports Second Quarter 2024 Financial Results
Express News | Omeros Corporation Q2 Net Income USD -56 Million
Express News | Omeros Corporation Q2 EPS USD -0.97
Here Is the Next Potential Market Catalyst
Omeros Q2 2024 Earnings Preview
Omeros Shares Rise on Balance Sheet Strengthening
Express News | Omeros Corporation has signed a credit agreement for a primary secured term loan facility of up to $92.10 million.
Express News | Omeros Corp: Entered Credit Agreement Which Provides for a Senior Secured Term Loan Facility Initially of up to $92.1 Mln
Omeros Corporation Further Strengthens Its Balance Sheet Through Series of Financing Transactions Extending Maturity on a Majority of Its Outstanding Debt Into 2028
Health Care Flat as Momentum Wanes -- Health Care Roundup
Why Fluent Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
SYTA, DATS and CYN Among Mid-day Movers
12 Health Care Stocks Moving In Thursday's Intraday Session
Omeros Plunges 20% Following Q1 Report, Drug Update
Omeros Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Adjusted EPS Results.
Needham: Reiterates that Omeros (OMER.US) holds the rating.
Needham: Reiterates that Omeros (OMER.US) holds the rating.